Bob joined PCI in 2019, and has been involved for more than 20 years in commercial biotechnology at firms of varying size and culture. He is knowledgeable about intellectual property strategy from the inventor’s perspective. Bob’s range of technological experience includes molecular design, synthesis, pharmacology, gene therapy, and drug development. He is the inventor of veledimex, the first clinical transcriptional activator for gene therapy.
Bob received his Ph.D. in chemistry from the University of Chicago and was an N.I.H. postdoctoral fellow at the Swiss Federal Institute of Technology (E.T.H.). Bob is PMP certified.